JP2022535550A5 - - Google Patents
Info
- Publication number
- JP2022535550A5 JP2022535550A5 JP2021571942A JP2021571942A JP2022535550A5 JP 2022535550 A5 JP2022535550 A5 JP 2022535550A5 JP 2021571942 A JP2021571942 A JP 2021571942A JP 2021571942 A JP2021571942 A JP 2021571942A JP 2022535550 A5 JP2022535550 A5 JP 2022535550A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- bone marrow
- marrow cells
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107222A JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857169P | 2019-06-04 | 2019-06-04 | |
| US62/857,169 | 2019-06-04 | ||
| US201962867569P | 2019-06-27 | 2019-06-27 | |
| US62/867,569 | 2019-06-27 | ||
| US201962947948P | 2019-12-13 | 2019-12-13 | |
| US62/947,948 | 2019-12-13 | ||
| US202063032214P | 2020-05-29 | 2020-05-29 | |
| US63/032,214 | 2020-05-29 | ||
| PCT/US2020/035702 WO2020247371A1 (en) | 2019-06-04 | 2020-06-02 | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107222A Division JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535550A JP2022535550A (ja) | 2022-08-09 |
| JP2022535550A5 true JP2022535550A5 (enExample) | 2023-06-12 |
| JP7716992B2 JP7716992B2 (ja) | 2025-08-01 |
Family
ID=73651973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571942A Active JP7716992B2 (ja) | 2019-06-04 | 2020-06-02 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
| JP2025107222A Pending JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107222A Pending JP2025129213A (ja) | 2019-06-04 | 2025-06-25 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12552873B2 (enExample) |
| EP (1) | EP3980463A4 (enExample) |
| JP (2) | JP7716992B2 (enExample) |
| KR (1) | KR20220042055A (enExample) |
| CN (1) | CN114401990A (enExample) |
| AU (1) | AU2020288823A1 (enExample) |
| BR (1) | BR112021024242A2 (enExample) |
| CA (1) | CA3141334A1 (enExample) |
| IL (1) | IL288510A (enExample) |
| TW (1) | TW202110891A (enExample) |
| WO (1) | WO2020247371A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| CA3141334A1 (en) * | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| US20220284243A1 (en) * | 2021-03-03 | 2022-09-08 | International Business Machines Corporation | Ensemble voting classifiers using adjusted thresholds |
| US12290565B2 (en) * | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| CN120682308B (zh) * | 2025-06-23 | 2025-12-02 | 北京昌盛鸿途生物科技有限公司 | 牛骨髓肽及其在提高免疫力中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001073028A2 (en) | 2000-03-24 | 2001-10-04 | Genetics Institute, Llc | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| CA2531283A1 (en) | 2003-06-30 | 2005-01-20 | Bio-Technology General (Israel) Ltd. | Specific human antibodies |
| CA2561835A1 (en) | 2004-03-30 | 2005-10-13 | Den Kgl. Veterinaer-Og Landbohojskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| WO2007033959A2 (en) * | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
| US7833530B2 (en) * | 2008-05-15 | 2010-11-16 | Selexys Pharmaceuticals Corporation | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies |
| WO2011143411A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
| EP2640629A1 (en) | 2010-11-18 | 2013-09-25 | Sean Michael Simpson | System and method for controlling a transmission of a human-powered vehicle |
| EP2654781B1 (en) * | 2010-12-21 | 2018-01-24 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| EP2718325A4 (en) * | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| WO2015077401A1 (en) | 2013-11-20 | 2015-05-28 | Drexel University | Compositions and methods for macrophage conversion |
| PT3166636T (pt) | 2014-07-08 | 2021-06-29 | Sanford Burnham Med Res Inst | Moduladores de psgl-1 e utilizações dos mesmos |
| US20170306042A1 (en) | 2014-08-29 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
| GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| EP3813881A4 (en) | 2018-06-29 | 2022-09-14 | Verseau Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF MONOCYTE AND MACROPHAGE INFLAMMATION PHENOTYPES AND IMMUNOTHERAPY USES THEREOF |
| CA3141334A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
-
2020
- 2020-06-02 CA CA3141334A patent/CA3141334A1/en active Pending
- 2020-06-02 WO PCT/US2020/035702 patent/WO2020247371A1/en not_active Ceased
- 2020-06-02 BR BR112021024242A patent/BR112021024242A2/pt unknown
- 2020-06-02 CN CN202080055123.9A patent/CN114401990A/zh active Pending
- 2020-06-02 US US17/615,863 patent/US12552873B2/en active Active
- 2020-06-02 JP JP2021571942A patent/JP7716992B2/ja active Active
- 2020-06-02 AU AU2020288823A patent/AU2020288823A1/en not_active Abandoned
- 2020-06-02 TW TW109118529A patent/TW202110891A/zh unknown
- 2020-06-02 KR KR1020217040138A patent/KR20220042055A/ko active Pending
- 2020-06-02 EP EP20818905.0A patent/EP3980463A4/en active Pending
-
2021
- 2021-11-29 IL IL288510A patent/IL288510A/en unknown
-
2025
- 2025-06-25 JP JP2025107222A patent/JP2025129213A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535550A5 (enExample) | ||
| JP2022535417A5 (enExample) | ||
| US12559718B2 (en) | Diagnostic methods for t cell therapy | |
| JP6788629B2 (ja) | 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法 | |
| ES2961666T3 (es) | Métodos para determinar la dosificación de células CAR-T | |
| JP2022540768A5 (enExample) | ||
| CN107438621B (zh) | 抗pd-1抗体 | |
| WO2019109053A1 (en) | Methods for dosing and for modulation of genetically engineered cells | |
| JP2023527410A5 (enExample) | ||
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JP2019513400A (ja) | エクスビボのｂｉｔｅ活性化ｔ細胞 | |
| WO2019222188A1 (en) | Methods of treating cancer | |
| US20240302349A1 (en) | Methods of assessing or monitoring a response to a cell therapy | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| KR20190117014A (ko) | 방광암의 항-pd-l1 항체 치료 | |
| JP2022539038A5 (enExample) | ||
| WO2019232479A2 (en) | Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods | |
| JP2023501487A (ja) | 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用 | |
| EP3388073A1 (en) | Targeting mesothelin in brain cancer | |
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| JP2026510915A (ja) | 免疫療法の有効性に対する腫瘍微小環境の影響 | |
| WO2026096859A2 (en) | Biomarkers related to immunotherapy efficacy | |
| WO2025199220A1 (en) | Post-infusion predictors of car t-cell therapy response |